ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1806 • 2018 ACR/ARHP Annual Meeting

    Spinal Cord Involvement in Behcet’s Disease- Experience of a Vasculitis Centre at Silk Road

    Ertugrul Cagri Bolek, Alper Sari, Levent Kilic, Ali Akdogan, Meryem Asli Tuncer and Omer Karadag, Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey

    Background/Purpose: Spinal cord involvement may occur in the course Behcet's Disease (BD). It may present with distinct manifestations such as sphincter and/or sexual dysfunction. We…
  • Abstract Number: 1807 • 2018 ACR/ARHP Annual Meeting

    Clinical Features and Disease Course of Neurologic Involvement in Behcet’s Disease

    Ertugrul Cagri Bolek, Alper Sari, Berkan Armagan, Abdulsamet Erden, Levent Kilic, Umut Kalyoncu, Meryem Asli Tuncer, Sedat Kiraz and Omer Karadag, Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey

    Background/Purpose: Neurological involvement (NBD) is a rare complication of BD. Although NBD is not common in the course of BD, it is related with significant…
  • Abstract Number: 1808 • 2018 ACR/ARHP Annual Meeting

    Increased Frequency of Obstructive Sleep Apnea Syndrome in Behcet’s Syndrome Patients with Vena Cava Superior Thrombosis

    Aycan Gokturk1, Sinem Nihal Esatoglu1, Yesim Ozguler1, Ersan Atahan2, Benan Musellim2, Vedat Hamuryudan1, Hasan Yazici3 and Emire Seyahi1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Pulmonary Medicine, Istanbul, Turkey, 3Istanbul Academic Hospital, Istanbul, Turkey

    Background/Purpose: Superior vena cava syndrome (SVCS), is a medical emergency and can also be seen in Behçet’s syndrome (BS). Contrary to the severe outcome seen…
  • Abstract Number: 1809 • 2018 ACR/ARHP Annual Meeting

    Clinical Characteristics of Older Age-Onset Behçet Syndrome Patients

    Gul Guzelant1, Yilmaz Ozyazgan2, Cem Mat3, Vedat Hamuryudan1, Hasan Yazici1 and Emire Seyahi1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 3Istanbul University, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, Turkey

    Background/Purpose: The usual onset of Behçet syndrome (BS) is in the 3. decade. Older age-onset defined as fulfilling the International Study Group (ISG) criteria after…
  • Abstract Number: 1810 • 2018 ACR/ARHP Annual Meeting

    Initial Visit Symptoms in Probable Behçet’s Predictive of ISG Criteria Behçet’s: Data from New York and Amsterdam Cohorts

    Floor Kerstens1, Christopher J. Swearingen2, Franktien Turkstra1 and Yusuf Yazici3, 1Amsterdam Rheumatology & Immunology Centre - Reade, Amsterdam, Netherlands, 2Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 3Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: Behçet’s syndrome (BS) is formally diagnosed using the International Study Group (ISG) criteria, where recurrent oral ulceration and any two other symptoms (recurrent genital…
  • Abstract Number: 1811 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of Interferon α2a As an Add-on Treatment for Refractory Behcet’s Uveitis

    Jing Shi1, Chan Zhao2, Jiaxin Zhou3, JinJing Liu1, Fei Gao2, Xiaofeng Zeng4, Meifen Zhang2 and Wenjie Zheng1, 1Rheumatology, Peking Union Medical College Hospital, Beijing, China, 2Department of Ophthalmology, Peking Union Medical College Hospital, Beijing, China, 3Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, 4Rheumatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China

    Background/Purpose: Uveitis is one of the leading causes of morbidity in Behcet’s patients which may result in irreversible vision loss. Evidence is accumulating that interferon…
  • Abstract Number: 1812 • 2018 ACR/ARHP Annual Meeting

    Characterization and Prevalence of Morbus Behçet in Switzerland

    Sabine Adler1, Rahel Villiger2, Lukas Buetikofer3 and Peter M. Villiger4, 1Department of Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, 2Rheumatology, Immunology and Allergology, University Hospital Bern, Switzerland, Bern, Switzerland, 3Clinical Trials Unit, University of Bern, Bern, Switzerland, 4Rheumatology and Clin Immunol, Bern, Switzerland

    Background/Purpose: To evaluate the clinical presentation of patients with Morbus Behçet (MB) in a cohort from Switzerland and to calculate the prevalence of MB in…
  • Abstract Number: 1813 • 2018 ACR/ARHP Annual Meeting

    Non-Aphthous Beginning As an Independent Risk Factor for the Course of Behçet’s Disease

    Muhammed Aydin1, Bahar Artim-Esen1, Murat Inanc2, Lale Ocal1 and Ahmet Gül1, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey

    Background/Purpose: Behçet disease (BD) is a multisystem inflammatory disorder characterized by recurrent manifestations in mucocutaneous tissues, eyes, joints, blood vessels, intestines and brain. Since there…
  • Abstract Number: 1814 • 2018 ACR/ARHP Annual Meeting

    Interferon-Alpha for the Management of Lower Extremity Deep Vein Thrombosis in Behcet’s Syndrome: A Case Series

    Yesim Ozguler1, Gulen Hatemi2, Firat Cetinkaya3, Koray Tascilar4, Serdal Ugurlu1, Emire Seyahi1, Hasan Yazici1 and Melike Melikoglu1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, 3Istanbul University, Cerrahpasa Medical Faculty, Department of Radiology, Istanbul, Turkey, 4Numune Research and Teaching Hospital, Ankara, Turkey

    Background/Purpose: Lower extremity deep vein thrombosis (LEDVT) is a disabling complication of Behcet’s syndrome (BS). Relapses are frequent and cause permanent disability due to post-thrombotic…
  • Abstract Number: 1815 • 2018 ACR/ARHP Annual Meeting

    Aneurysmal Lesions in Behcet’s Disease: A Report of 69 Cases from a Single Center

    Jiaxin Zhou1, Jing Shi2, Xiuhua Wu2, JinJing Liu2 and Wenjie Zheng2, 1Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, 2Rheumatology, Peking Union Medical College Hospital, Beijing, China

    Background/Purpose: To analyze the clinical features of patients with Behcet’s disease(BD) complicated with aneurysmal lesions. Methods: We retrospectively reviewed the clinical data of patients with…
  • Abstract Number: 1816 • 2018 ACR/ARHP Annual Meeting

    Five-Year Outcome of Operative and Nonoperative Management of Meniscal Tear in the Presence of Osteoarthritic Changes

    Jeffrey N. Katz1, Swastina Shrestha2, Elena Losina3, Lisa A. Mandl4, Bruce Levy5, Kurt Spindler6 and Jamie E. Collins7, 1Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 2Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 3Orthopaedics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 4Rheumatology, Hospital for Special Surgery, New York, NY, 5Orthopedics, Mayo Clinic, Rochester, MN, 6Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, OH, 7Department of Orthopedic Surgery, Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: While recent trials have examined short-term (~ 2 year) outcomes of surgical and nonoperative treatment of meniscal tear in the setting of osteoarthritis there…
  • Abstract Number: 1817 • 2018 ACR/ARHP Annual Meeting

    MicroRNA-128 Impairs Cartilage Integrity and Deteriorates Osteoarthritis Pathogenesis through Deregulating Chondrocyte Autophagy

    Feng-Sheng Wang1, Wei-Shiung Lian2, Yi-Chih Sun1, Jih-Yang Ko3 and Yu-Shan Chen1, 1Core Facility for Phenomics & Diagnostics, Department of Medical Research, Core Facility for Phenomics & Diagnostics, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital, Taiwan, Kaohsiung, Taiwan, 2Core Facility for Phenomics & Diagnostics, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital, Taiwan, Kaohsiung, Taiwan, 3Department of Orthopedic Surgery, Department of Orthopedic Surgery, Kaohsiung Chang Gung Memorial Hospital, Taiwan, Kaohsiung, Taiwan

    Background/Purpose: Autophagy gets rids of unwanted proteins or organelle keeping cells to stay functional upon encountering adverse stresses. While non-coding microRNAs interfere with mRNA targets…
  • Abstract Number: 1818 • 2018 ACR/ARHP Annual Meeting

    Greater BMD Gains with Denosumab Vs Risedronate in Glucocorticoid-Treated Subjects: Results from the Final 24-Month Analysis of a Randomized, Double-Blind, Double-Dummy Study

    Kenneth Saag1, Nicola Pannacciulli2, Piet Geusens3, Jonathan D. Adachi4, Osvaldo D. Messina5, Jorge Morales-Torres6, Ronald Emkey7, Peter W. Butler2, Xiang Yin2 and Willem F. Lems8, 1University of Alabama at Birmingham, Birmingham, AL, 2Amgen Inc., Thousand Oaks, CA, 3Maastricht University, Maastricht, Netherlands, 4McMaster University, Hamilton, ON, Canada, 5Cosme Argerich Hospital, Buenos Aries, Argentina, 6Hospital Aranda de la Parra, Leon, Mexico, 7Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, 8VU University Medical Centre, Amsterdam, Netherlands

    Background/Purpose: Denosumab 60 mg subcutaneously every 6 months (Q6M) increased spine and hip BMD significantly more than risedronate 5 mg orally once daily (QD) at…
  • Abstract Number: 1819 • 2018 ACR/ARHP Annual Meeting

    MUC5B promoter Variant rs35705950 Is a Risk Factor for Rheumatoid Arthritis – Interstitial Lung Disease

    Pierre-Antoine Juge1, Joyce Sujin Lee2, Esther Ebstein1, Hiroshi Furukawa3, Evgenia Dobrinskikh4, Steven Gazal5, Caroline Kannengiesser5, Sébastien Ottaviani1, Shomi Oka6, Shigeto Tohma7, Naoyuki Tsuchiya8, Jorge Rojas-Serrano9, Montserrat I. González-Pérez9, Mayra Mejía9, Ivette Buendía-Roldán9, Ramcés Falfan-Valencia10, Enrique Ambrocio-Ortiz10, Effrosyni Manali11, Spyros A. Papiris11, Theofanis Karageorgas12, Dimitrios Boumpas12, Katarina Antoniou13, Coline H.M. van Moorsel14, Joanne van der Vis14, Yaël A. de Man14, Jan C. Grutters14, Yaping Wang15, Raphaël Borie16, Lidwine Wemeau-Stervinou17, Benoit Wallaert18, René-Marc Flipo19, Hilario Nunes20, Dominique Valeyre20, Nathalie Saidenberg21, Marie-Christophe Boissier22, Sylvain Adam-Marchand23, Aline Frazier24, Pascal Richette25, Yannick Allanore26, Jean Sibilia27, Claire Dromer28, Christophe Richez29, Thierry Schaeverbeke30, Huguette Lioté31, Gabriel Thabut32, Nadia Nathan33, Serge Amselem34, Martin Soubrier35, Vincent Cottin36, Annick Clément33, Kevin D. Deane37, Avram D. Walts4, Tasha Fingerlin38, Aryeh Fischer39, Jay H. Ryu40, Eric L. Matteson41, Timothy B. Niewold42, Deborah Assayag43, Andrew Gross44, Paul Wolters45, Marvin I. Schwartz46, V. Michael Holers47, Joshua J. Solomon48, Tracy Doyle49, Ivan O. Rosas50, Cornelis Blauwendraat51, Mike A. Nalls52, Marie-Pierre Debray16, Catherine Boileau5, Bruno Crestani16, David A. Schwartz4 and Philippe Dieude16, 1Rhumatologie, Hôpital Bichat - Claude Bernard, Paris, France, 2SOM-MED, University of Colorado, Denver - Anschutz Medical Campus, Aurora, CO, 3University of Tsukuba, Graduate School of Comprehensive Human Sciences, Masters' Program in Medical Sciences, Tsukuba, Japan, 4Department of Medicine, University of Colorado School of Medicine, Aurora, CO, 5Génétique, Hôpital Bichat - Claude Bernard, Paris, France, 6Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hopsital, Sagamihara, Japan, 7Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, 8Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 9Interstitial Lung Disease & Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, 10HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, 112nd Pulmonary Medicine Department, University Hospital of Athens "Attikon", Athens, Greece, 12Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, University Hospital of Athens "Attikon", Athens, Greece, 13PS Department of Respiratory Medicine & Laboratory of Molecular & Cellular Pneumonology, University of Crete, Crete, Greece, 14St Antonius ILD center of excellence, St Antonius ziekenhuis, Nieuwegein, Netherlands, 15Department of Medical Genetics, Nanjing University School of Medicine, Nanjing, China, 16Université Paris-Diderot, Paris, France, 17Pneumologie, CHRU de Lille, Lille, France, 18Pneumology, CHRU, Lille CEDEX, France, 19Hôpital Roger Salengro, Lille, France, 20Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, 21Rhumatologie, Hôpital Avicenne, Paris, France, 2274 rue Marcel Cachin, INSERM, Bobigny, France, 23Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France, 24Rhumatologie, Hôpital Lariboisière, Paris, France, 25Rheumatology, Université Paris Diderot, Paris, France, 26Rhumatologie A, Hôpital Cochin, Paris, France, 27Université de Strasbourg, Strasbourg, France, 28Imagerie Thoracique et Cardiovasculaire, CHU Bordeaux, Bordeaux, France, 29Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, 30Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France, 31Pneumologie A, Hôpital Tenon, Paris, France, 32Pneumologie B, Hôpital Bichat - Claude Bernard, Paris, France, 33Pneumologie pédiatrique, Hôpital Trousseau, Paris, France, 34Service de Pneumologie Pédiatrique et Centre de référence des maladies respiratoires rares, Hôpital Trousseau, Paris, France, 35Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 36Lyon Louis Pradel, Lyon, France, 37Division of Rheumatology, University of Colorado Denver, Aurora, CO, 38Department of Biomedical Research, National Jewish Health, Denver, CO, 39Rheumatology / ILD Program, National Jewish Health, Denver, CO, 40Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, 41Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 42Colton Center for Autoimmunity, New York University School of Medicine, New York, NM, 43McGill University, Department of Medicine, Montreal, QC, Canada, 44Department of Medicine, University of California, San Francisco, CA, 45Pulmonary Division, Department of Medicine, University of California, San Francisco, San Francisco, CA, 46University of Colorado School of Medicine, Department of Medicine, Aurora, CO, 47Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 48Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO, 49Brigham and Women's Hospital, Boston, MA, 50BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA, 51Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, 52Data Tecnica International, Glen Echo, MD

    Background/Purpose: Given phenotypic similarities between rheumatoid arthritis–associated interstitial lung disease (RA-ILD) and idiopathic pulmonary fibrosis (IPF), we hypothesized that the strongest risk factor for the…
  • Abstract Number: 1820 • 2018 ACR/ARHP Annual Meeting

    Myeloablative Autologous Hematopoietic Stem Cell Transplantation for Severe Scleroderma: Long-Term Outcomes 6-11 Years after Entry on a Randomized Study Comparing Transplantation and Cyclophosphamide

    Keith Sullivan1, Ashley Pinckney2, Ellen Goldmuntz3, Beverly Welch4, Dinesh Khanna5, Robert W. Simms6, Suzanne Kafaja7, George Georges8, Jan Storek9, Mary Ellen Csuka10, Richard Nash11, Daniel E. Furst12, Leslie Crofford13, Peter McSweeney11, Maureen D. Mayes14 and Lynette Keyes-Elstein15, 1Duke University Medical Center, Durham, NC, 2Rho Federal Systems, Inc., Chapel Hill, NC, 3NIAID, NIH, Bethesda, MD, 4National Institutes of Health, Bethesda, MD, 5Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 6Rheumatology, Boston University School of Medicine, Boston, MA, 7David Geffen School of Medicine, UCLA, Los Angeles, CA, 8Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, 9University of Calgary, Calgary, AB, Canada, 10Medicine, Medical College of Wisconsin, Milwaukee, WI, 11Colorado Blood Cancer Institute, Denver, CO, 12University of Washington, Seattle, WA, 13Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 14Rheumatology, University of Texas McGovern Medical School, Houston, TX, 15Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC

    Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated that for adults with severe scleroderma (ACR 1995 criteria) and internal organ involvement, myeloablative CD34+selected autologous…
  • « Previous Page
  • 1
  • …
  • 1123
  • 1124
  • 1125
  • 1126
  • 1127
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology